Target intelligence / Profile preview

Serotonin receptor 5-HT3 subtype (5-HT3 receptor)

Target
5-HT3 receptor
Molecular classification
Ion channel, Ligand-gated ion channel, Cys-loop receptor family, Receptor
01

Overview

The Serotonin receptor 5‑HT3 subtype is a ligand-gated ion channel belonging to the Cys-loop superfamily. Unlike other serotonin receptors that are G protein-coupled, the 5‑HT3 receptor forms a pentameric structure around a central pore permeable primarily to cations. Functional channels can be homopentamers composed solely of 5‑HT3A subunits or heteropentamers including other subunits such as 5‑HT3B–E. The receptor is widely expressed throughout both central and peripheral nervous systems, mediating rapid excitatory synaptic transmission. It plays key roles in emesis pathways—making it an important therapeutic target for antiemetic drugs—as well as modulating anxiety and possibly seizure susceptibility. Its antagonists are clinically used mainly for prevention of chemotherapy-induced nausea and vomiting but may have additional neuropsychiatric applications. Safety concerns include cardiac arrhythmias due to QT prolongation with certain drugs targeting this molecule.

Other names
5-hydroxytryptamine receptor 3HTR3Serotonin-gated ion channel5-HT₃ (common abbreviation in literature)
02

Mechanism of action

Antagonists block serotonin binding, preventing activation of the ion channel, thereby inhibiting fast excitatory neurotransmission associated with nausea/vomiting centers in the brainstem. Agonists open the cation-selective ion channel, leading to neuronal excitation.

03

Biological functions

Fast excitatory synaptic transmission in the central and peripheral nervous systemsModulation of neurotransmitter releaseRegulation of neuronal development and dendrite complexity
04

Disease associations

Nausea and vomiting (especially chemotherapy-induced)Anxiety disordersSeizure modulation/anticonvulsant activity
05

Safety considerations

Potential for QT interval prolongation with some antagonists (e.g., ondansetron).Possible CNS side effects such as headache or dizziness.Risk of constipation or gastrointestinal disturbances due to peripheral blockade.
06

Interacting drugs

Ondansetron (antagonist)

2 more in the full profile.

07

Biomarkers

No widely established biomarkers for patient selection or efficacy monitoring specific to this target; clinical response is typically used.

Beyond the preview

Go deeper on Serotonin receptor 5-HT3 subtype (5-HT3 receptor).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin receptor 5-HT3 subtype (5-HT3 receptor).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call